Novartis CEO Circumspect About Biotech Bargains
As Renowned Analyst Ronny Gal Jumps Aboard
Vas Narasimhan tells Scrip that a return to sensible valuations of biotechs could lead to increased deal-making but cautions that a number of those companies that went public "may not have been mature enough with their science” and their true value remains unclear.
